Cisplatin 200mg
| Product Overview | |
| Generic Name | Cisplatin 200mg |
| Brand Name(s) | Platinol-AQ |
| Form | Multi-Use Vial for Intravenous use |
| Strength | 200 mg/200 mL |
| Therapeutic Class | Platinum-based alkylating antineoplastic agent |
| ATC Code | L01XA01 |
| Manufacturing & Regulatory | |
| Manufacturer | Bristol-Myers Squibb |
| Country | Canada, USA, India |
| GMP Compliance | WHO-GMP |
| DMF/CEP | #75-036 |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 10 units |
| Shelf Life | 24 months |
| Storage | 2–8 °C |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes—lot-specific Certificate of Analysis |
| CTD Summary | CTD from originator; generic use abbreviated formats |
Description
Cisplatin is an injectable platinum-based chemotherapy medicine used under specialist oncology supervision for the treatment of several solid tumors, including testicular, ovarian, bladder, lung, cervical, and head-and-neck cancers. It is administered by intravenous infusion and requires close monitoring due to potential kidney toxicity, bone marrow suppression, hearing toxicity, nausea/vomiting, and electrolyte abnormalities.
